{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-24-000029","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.309977+00:00","generated_at":"2026-06-02T21:29:12.024771+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ligand reports Q1 revenue $31M; net income $86.1M on Viking gain; reaffirms guidance; $100M Agenus royalty deal","bullets":["Q1 total revenue $31.0M vs $44.0M last year; royalties up $19.1M from $17.6M.","Net income $86.1M ($4.75 diluted) vs $43.6M, includes $60M realized gain on Viking stock.","Core adjusted EPS $1.20 vs $1.33; decrease due to prior-year $15.3M Travere milestone.","Reaffirms 2024 guidance: total revenue $130-142M, core adjusted EPS $4.25-4.75.","Entered $100M royalty financing with Agenus for six partnered oncology programs; $75M upfront."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-24-000029","json":"https://secwatch.observer/filing/0000886163-24-000029.json","markdown":"https://secwatch.observer/filing/0000886163-24-000029.md","text":"https://secwatch.observer/filing/0000886163-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000029/0000886163-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000029/lgnd-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:29:12.024771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d0ec6178885f6bd55d2824628e055d14649b8144","claim":"LIGAND PHARMACEUTICALS INC reported 2024 results: revenue $130 million to $142 million, EPS approximately $4.25 to $4.75. Guidance reaffirmed.","evidence_excerpt":"Ligand is reaffirming its 2024 financial guidance. The Company expects 2024 royalties ranging from $90 million to $95 million, sales of Captisol to range from $25 million to $27 million, and contract revenue ranging from $15 million to $20 million. These revenue components result in total revenue forecast of $130 million to $142 million. Ligand notes that with total revenue of $130 million to $142 million, core adjusted earnings per diluted share are expected to range from approximately $4.25 to $4.75.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000029/0000886163-24-000029-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2024"},{"label":"Revenue","value":"$130 million to $142 million"},{"label":"EPS","value":"approximately $4.25 to $4.75"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e13a52d01811467eac040921fe03b5393d0aebe0","claim":"LIGAND PHARMACEUTICALS INC reported the three months ended March 31, 2024 results: revenue $31.0 million, net income $86.1 million, EPS $4.75 per diluted share.","evidence_excerpt":"Total revenues and other income for the first quarter of 2024 were $31.0 million, compared with $44.0 million for the same period in 2023. Royalties for the first quarter of 2024 were $19.1 million, compared with $17.6 million for the same period in 2023, with the increase primarily attributable to Amgen’s (Nasdaq: AMGN) Kyprolis, Jazz Pharmaceuticals' (Nasdaq: JAZZ) RYLAZE, Merck and Co.’s (NYSE: MRK) VAXNEUVANCE and Travere Therapeutics’ (Nasdaq: TVTX) FILSPARI, partially offset by a decline in CASI’s (Nasdaq: CASI) EVOMELA. Captisol sales were $9.2 million for the first quarter of 2024, compared with $10.6 million for the same period in 2023, with the change due to the timing of customer orders. Contract revenue and other income was $2.7 million for the first quarter of 2024, compared with $15.7 million for the same period in 2023, with the difference driven by a $15.3 million milestone payment earned from Travere Therapeutics upon the FDA approval of FILSPARI in the prior year quar","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000029/0000886163-24-000029-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$31.0 million"},{"label":"Net income","value":"$86.1 million"},{"label":"EPS","value":"$4.75 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}